Breast Neoplasm Clinical Trial
— INNOVBCOfficial title:
Self-care Programs in Oncology: a Guided Internet-delivered Individually-tailored Acceptance and Commitment Therapy (ACT)-Influenced Cognitive Behavioural Intervention to Improve Psychosocial Outcomes in Breast Cancer Survivors
Background: Internet-delivered interventions (IDI) can provide remarkable opportunities in
addressing breast cancer (BC) survivors' unmet needs, as they present an effective strategy
to improve care coordination and provide access to efficacious, cost-efficient and convenient
survivorship care. Nevertheless, research focusing on this field and aiming at improving
survivors´ psychosocial needs is scarce and its practical implementation is limited.
Objectives: This study aims at studying BC patients´ and healthcare providers' attitudes
towards IDI; exploring BC patients´ unmet support needs and; determining the acceptability,
feasibility, efficacy and cost-effectiveness of iACT-BC, a guided internet-delivered
individually-tailored ACT-influenced cognitive behavioural intervention designed to improve
psychosocial outcomes in BC survivors when compared to treatment as usual. The primary
outcomes in this research are anxiety and depression. Secondary outcomes include
psychological flexibility, fatigue, insomnia, Sexual dysfunction (SD) and Health Related
Quality of Life.
Methods: A multimethod research design will be applied and two consecutive studies will be
performed. Study 1 will explore participants´ attitudes towards IDI as well as, BC patients'
psychosocial unmet needs by adopting an exploratory cross-sectional study design. Study 2
will investigate the effectiveness and cost-effectiveness of iACT-BC in BC survivors, by
implementing a two-arm, parallel, open label, multicentre, waiting list randomized controlled
trial.
Expected Results: It is anticipated that iACT-BC will show to be an effective and
cost-effective program in improving anxiety, depression, psychological flexibility, fatigue,
insomnia, SD and HRQoL in BC survivors, as opposing to a waiting list control under treatment
as usual. The results of this research will be published in accordance with CONSORT 2010 and
CONSORT-EHEALTH guidelines and should be available for publication in February 2020.
Status | Not yet recruiting |
Enrollment | 128 |
Est. completion date | December 2019 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Signed written informed consent. - Age = 18 years; - Ability to read and write in Portuguese. - History of histologically or cytologically confirmed breast cancer with no evidence of metastatic disease. - An interval = 6 month from primary adjuvant treatment completion (surgery, chemotherapy and/or radiotherapy), except for hormonal therapy. - Clinically significant symptoms of at least one of the following conditions: anxiety, depression, fatigue, insomnia and/or sexual dysfunction. - Ongoing regular psychoactive medication only accepted if dosage has been stable during the last 3 months. - Daily access to the Internet by computer and/or smartphone. - Ability to use a computer and/or smartphone and the internet. - No participation on any other interventional study or clinical trial. Exclusion Criteria: - Age = 18 years; - Inability to co-operate and give informed consent. - Breast cancer not histologically or cytologically confirmed. - History of other malignancy within the last 5 years. - Metastasized breast cancer. - Current severe, uncontrolled systemic disease or mental disorder. - Absence of clinically significant symptoms. - Parallel ongoing psychological treatment. - Ongoing regular psychoactive medication if dosage has been changed during the last 3 months. - No access to the internet. - Inability to use a computer and/or smartphone and the internet. - Parallel ongoing participation in other interventional study or clinical trial. - Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Linkoeping University | Escola Nacional de Saúde Pública - Universidade Nova de Lisboa |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Participants' attitudes towards internet interventions | Attitudes towards internet interventions survey (ATTIS) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Other | Breast cancer patients' unmet support needs | Supportive Care Needs Survey Questionnaire (SCNS-SF34) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Other | Intervention cost-effectiveness | Questionnaire on Medical consumption and Productivity losses associated with Psychiatric Illness (TIC-P) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Other | Intervention cost-utility | EuroQol EQ-5D-5L | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Primary | Depression | Patient Health Questionnaire (PHQ-9) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Primary | Anxiety | Generalized Anxiety Disorder Scale (GAD-7) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Psychological flexibility | Cancer Acceptance and Action Questionnaire (Cancer AAQ) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Fatigue | Brief Fatigue Inventory (BFI) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Insomnia | Insomnia Severity Index (ISI) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Sexual dysfunction | Female Sexual Function Index (FSFI) | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Health related quality of life - generic measure | EORTC QLQC30 | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months | |
Secondary | Health related quality of life - breast cancer specific measure | EORTC QLQBR23 | Change from baseline to post-intervention (10 weeks after enrollment), Follow-ups at 3, 6 and 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03273426 -
Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.
|
N/A | |
Recruiting |
NCT04583124 -
Adjusting the Dose of Therapeutic Exercise to Prevent Neurotoxicity Due to Anticancer Treatment (ATENTO)
|
N/A | |
Active, not recruiting |
NCT04489173 -
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer
|
Phase 2 | |
Recruiting |
NCT02913573 -
Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction
|
Phase 2 | |
Completed |
NCT03124095 -
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
|
N/A | |
Terminated |
NCT00251095 -
Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT05576545 -
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment
|
N/A | |
Active, not recruiting |
NCT03625635 -
Effect of a Clinical Nutrition Intervention Program in Breast Cancer Patients During Antineoplastic Treatment
|
N/A | |
Recruiting |
NCT04799535 -
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
|
||
Withdrawn |
NCT03266562 -
Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography
|
N/A | |
Completed |
NCT00530868 -
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
|
Phase 2 | |
Recruiting |
NCT06255808 -
Development of Assist Tool for Breast Examination Using the Principle of Ultrasonic Sensor
|
||
Completed |
NCT04640220 -
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors
|
N/A | |
Completed |
NCT02970682 -
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT02316561 -
Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer
|
N/A | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Terminated |
NCT00249301 -
A Study of MLN8054 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06056414 -
Study of Anxiety After a Session of Energy Resonance by Cutaneous Stimulation
|
N/A | |
Recruiting |
NCT05427071 -
Magnetic Marker Localization for Occult Breast Cancer and Target Axillary Dissection in Node-positive Breast Cancer Post-neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT03740893 -
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
|
Phase 2 |